Evidence map›Paper›PMID 29313265›Full record

SynthesisThe patient2018

A Systematic Review of Discrete-Choice Experiments and Conjoint Analysis Studies in People with Multiple Sclerosis.

Edward J D Webb, David Meads, Ieva Eskyte, Natalie King, Naila Dracup, Jeremy Chataway, Helen L Ford, Joachim Marti, Sue H Pavitt, Klaus Schmierer and 1 more

Open access · greenAbstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in The patient, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 3 pooled it
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 3 syntheses or guidelines pooled it, 49 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Association of medication adherence with treatment preferences: incentivizing truthful self-reporting.The European journal of health economics : HEPAC : health economics in prevention and care · 2025
    Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Clinical Decision-Making for Appendectomy in Kosovo: A Conjoint Analysis.International journal of environmental research and public health · 2022
    Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 2 countries.

Edward J D WebbLeeds Institute for Health Sciences, University of Leeds, Leeds, UK. e.j.d.webb@leeds.ac.uk.
David MeadsLeeds Institute for Health Sciences, University of Leeds, Leeds, UK.
Ieva EskyteSchool of Dentistry, University of Leeds, Leeds, UK.
Natalie KingLeeds Institute for Health Sciences, University of Leeds, Leeds, UK.
Naila DracupLeeds Institute for Health Sciences, University of Leeds, Leeds, UK.
Jeremy ChatawayQueen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Institute of Neurology, University College London, London, UK.
Helen L FordLeeds Teaching Hospitals NHS Trust, Leeds, UK.
Joachim MartiInstitute of Social and Preventive Medicine (IUMSP), Centre Hospitalier Universitaire Vaudois, Université de Lausanne, Lausanne, Switzerland.
Sue H PavittDental Translational and Clinical Research Unit, School of Dentistry, University of Leeds, Leeds, UK.
Klaus SchmiererBlizard Institute (Neuroscience) Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
Ana ManzanoSchool of Sociology and Social Policy, University of Leeds, Leeds, UK.
University of Leeds · GBLeeds Dental Hospital · GBLeeds Teaching Hospitals NHS Trust · GBQueen Mary University of London · GBUniversity College London · GBUniversity Hospital of Lausanne · CH

Funding

Multiple Sclerosis Society 30
6 · The paper itself

Abstract

backgroundMultiple sclerosis (MS) is a chronic disabling, inflammatory, and degenerative disease of the central nervous system that, in most cases, requires long-term disease-modifying treatment (DMT). The drugs used vary in efficacy and adverse effect profiles. Several studies have used attribute-based stated-preference methods, primarily to investigate patient preferences for initiating or escalating DMT.

objectivesTo conduct a systematic review of attribute-based stated-preference studies in people with MS to identify common methods employed and to assess study quality, with reference to the specific challenges of this disease area.

methodsWe conducted a systematic search for studies related to attribute-based stated-preference and MS in multiple databases, including Cochrane and MEDLINE. Studies were included if they were published in a peer-reviewed journal, were on the topic of MS, and used a survey methodology that measured stated preferences for attributes of a whole. Analysis was conducted using narrative synthesis and summary statistics. Study quality was judged against the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) conjoint analysis checklist.

resultsWe identified 16 relevant articles reporting 17 separate studies, all but one focusing on DMTs. Most studies were discrete-choice experiments. Study quality was generally high, but we recommend the following: (1) that consideration of sample sizes be improved, (2) that survey design choices be justified and documented, (3) that qualitative approaches for attribute and level selection be incorporated to better involve patients, and (4) that reporting of experimental practice be improved. The effects of DMTs on reproduction and the impact of how risk and uncertainty are presented were identified as neglected research topics. The ISPOR conjoint analysis checklist was found to be unsuitable for the assessment of study quality.

conclusionAttribute-based stated preference is a useful method with which to examine the preferences of people with MS in their choice of DMT. However, further research embracing the methodological recommendations identified, particularly greater use of qualitative methods in attribute development, is needed.

Indexed as

Patient PreferenceChoice BehaviorDecision MakingDecision Support TechniquesDrug Administration RoutesDrug Administration ScheduleHumansImmunosuppressive AgentsMultiple SclerosisQualitative ResearchQuality of LifeResearch DesignImmunosuppressive Agents

Identifiers

PMID29313265
OpenAlexW2782724327

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.